ClinicalTrials.Veeva

Menu
T

Trials365, LLC. | Shreveport, LA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Platinum
ACR-368
Trastuzumab
TIVDAK
Bevacizumab
INCB123667

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitiza...

Enrolling
Endometrial Adenocarcinoma
Drug: ACR-368
Drug: Gemcitabine

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpre...

Enrolling
Ovarian Cancer
Drug: INCB123667

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop th...

Enrolling
Cervical Cancer
Drug: TIVDAK

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinom...

Enrolling
Endometrial Cancer
Drug: Matching Placebo for selinexor
Drug: Selinexor

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-...

Enrolling
Ovarian Cancer
Drug: Trastuzumab Deruxtecan
Drug: Bevacizumab
Locations recently updated

This phase 3 study will be conducted in different countries all over the world.The purpose of this study is to compare how well Rina-S works against...

Enrolling
Platinum-resistant Ovarian Cancer
Drug: Topotecan
Drug: Gemcitabine

The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubici...

Enrolling
Platinum-resistant Ovarian Cancer
Drug: NP-G2-044
Drug: PLD

Trial sponsors

A
Daiichi Sankyo logo
Genmab logo
Incyte logo
I
Karyopharm Therapeutics logo
N
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems